Other
Vaccines
0
Pipeline Programs↗
2
Active Trials↗
6
Companies Involved↗
Vaccines is an early-stage landscape with 0 programs across 6 companies. The most active players are GSK, Sanofi, Pfizer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
45
clinical trials
Completed37 · 82%
Unknown status3 · 7%
Terminated2 · 4%
Recruiting1 · 2%
Active, not recruiting1 · 2%
Suspended1 · 2%
Clinical Trials
Trial Activity
45 trials
Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00107549·20 enrolled
Ebola and Marburg Virus Vaccines
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00605514·20 enrolled
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
Completed·—·Phase 4·NCT02787863·219 enrolled
Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines
Completed·—·Phase 4·NCT03530124·223 enrolled
Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00056745·12 enrolled
Live Vaccines and Innate Immune Training in COPD.
Completed·—·Phase 4·NCT06257212·60 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)